A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory/relapsed diffuse large B-cell lymphoma by Robin Noel, Christophe Zemmour, Catalina Montes de Oca, Nawel Belmecheri, Thérèse Aurran-Schleinitz, Diane Coso, Leonor Lopez Almeida, Lénaïg Mescam, Norbert Vey, Jean Sébastien Bladé, Borhane Slama, Reda Bouabdallah, Jean-Marc Schiano de Colella

Get full text